Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027627 (
metastases
)
103,950
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Ovarian cancer is a highly invasive and
metastatic disease
with a poor prognosis if diagnosed at an advanced stage, which is often the case. Recent studies argue that ovarian cancer cells that have undergone epithelial-to-mesenchymal transition (EMT) acquire aggressive malignant properties, but the relevant molecular mechanisms in this setting are not well-understood. Here, we report findings from an siRNA screen that identified the homeobox transcription factor
ALX1
as a novel regulator of EMT. RNA interference-mediated attenuation of
ALX1
expression restored E-cadherin expression and cell-cell junction formation in ovarian cancer cells, suppressing cell invasion, anchorage-independent growth, and tumor formation. Conversely, enforced expression of
ALX1
in ovarian cancer cells or nontumorigenic epithelial cells induced EMT. We found that
ALX1
upregulated expression of the key EMT regulator Snail (SNAI1) and that it mediated EMT activation and cell invasion by
ALX1
. Our results define the
ALX1
/Snail axis as a novel EMT pathway that mediates cancer invasion.
...
PMID:ALX1 induces snail expression to promote epithelial-to-mesenchymal transition and invasion of ovarian cancer cells. 2328 9
Osteosarcoma is the most common primary malignant tumor in children and young adults, and the molecular regulation of the invasion of osteosarcoma (OS) remains unknown. In this study, we found that increased expression of
ALX1
was associated with the progression of osteosarcoma and that
ALX1
protein levels were significantly elevated in matched distant
metastases
. High
ALX1
levels also predict shorter overall survival of osteosarcoma patients. We investigated the therapeutic potential of targeting
ALX1
expression using the technique of RNA silencing via short hairpin RNA (shRNA). Synthetic shRNA duplexes against
ALX1
were introduced to downregulate the expression of
ALX1
in a highly malignant osteosarcoma cell line, U2OS. The results obtained indicated that shRNA targeting of
ALX1
could lead to an efficient and specific inhibition of endogenous
ALX1
activity. Furthermore, we found that depletion of
ALX1
caused a dramatic cell cycle arrest, followed by massive apoptotic cell death, and eventually resulted in a significant decrease in migration and invasion of the osteosarcoma cell line studied.
...
PMID:Depletion of ALX1 causes inhibition of migration and induction of apoptosis in human osteosarcoma. 2573 24
Molecular signatures specific to particular tumor types are required to design treatments for resistant tumors. However, it remains unclear whether tumors and corresponding cell lines used for drug development share such signatures. We developed similarity core analysis (SCA), a universal and unsupervised computational framework for extracting core molecular features common to tumors and cell lines. We applied SCA to mRNA/miRNA expression data from various sources, comparing melanoma cell lines and
metastases
. The signature obtained was associated with phenotypic characteristics in vitro, and the core genes CAPN3 and TRIM63 were implicated in melanoma cell migration/invasion. About 90% of the melanoma signature genes belong to an intrinsic network of transcription factors governing neural development (TFAP2A, DLX2,
ALX1
, MITF, PAX3, SOX10, LEF1, and GAS7) and miRNAs (211-5p, 221-3p, and 10a-5p). The SCA signature effectively discriminated between two subpopulations of melanoma patients differing in overall survival, and classified MEKi/BRAFi-resistant and -sensitive melanoma cell lines.
...
PMID:New Functional Signatures for Understanding Melanoma Biology from Tumor Cell Lineage-Specific Analysis. 2648 59